Free Trial
NASDAQ:GCBC

Greene County Bancorp Q1 2025 Earnings Report

Greene County Bancorp logo
$21.41 +0.01 (+0.05%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$21.32 -0.09 (-0.44%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greene County Bancorp EPS Results

Actual EPS
$0.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Greene County Bancorp Revenue Results

Actual Revenue
$31.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Greene County Bancorp Announcement Details

Quarter
Q1 2025
Time
During Market Hours
Conference Call Date
Tuesday, October 22, 2024
Conference Call Time
11:30AM ET

Upcoming Earnings

Greene County Bancorp's Q3 2025 earnings is scheduled for Monday, April 21, 2025, with a conference call scheduled on Tuesday, April 22, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cidara Therapeutics Earnings Headlines

Greene County Bancorp's (NASDAQ:GCBC) Dividend Will Be $0.09
New “Trump” currency proposed in DC
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Greene County Bancorp, Inc. Announces Cash Dividend
See More Greene County Bancorp Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cidara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cidara Therapeutics and other key companies, straight to your email.

About Cidara Therapeutics

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

View Cidara Therapeutics Profile

More Earnings Resources from MarketBeat